Release Date |
|
| May 15, 2012 |
Advaxis Retires $4.5 Million in Debt, Adds $1,240,000 in New Financing |
| May 8, 2012 |
Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer |
| May 2, 2012 |
Advaxis Announces Abstracts Accepted for Poster Presentation at ASCO Annual Meeting 2012 |
| May 1, 2012 |
Advaxis Research Accepted for American Association of Immunologists Annual Meeting, Demonstrates Reduction of Tumor Defenses |
| Apr 25, 2012 |
Advaxis to Speak at 2012 World Immunotherapy Online Symposium |
| Apr 12, 2012 |
Advaxis Awarded Best Therapeutic Vaccine |
| Apr 10, 2012 |
Advaxis Announces Presentations at World Vaccine Congress 2012 |
| Apr 5, 2012 |
Advaxis Announces Collaboration with the Karolinska Institutet |
| Mar 28, 2012 |
Advaxis Announces Abstracts Accepted for Poster Presentation at AACR Annual Meeting 2012 |
| Mar 21, 2012 |
Advaxis Continues Collaboration with Former NCI Vaccines Chief in New Position as Director of the Georgia Health Sciences University Cancer Center |
| Mar 19, 2012 |
Advaxis Named to Shortlist for Vaccine Industry Excellence Award |
| Mar 16, 2012 |
Advaxis to Present at the 6th Annual International BIO-Europe Spring 2012 Conference |
| Feb 27, 2012 |
Advaxis Low Dose Cohort 1 Meets 50% Efficacy Target In CIN 2/3 |
| Feb 9, 2012 |
Advaxis to Present at the 14th Annual BIO CEO & Investor Conference |
| Jan 26, 2012 |
REPEAT/Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer |
| Jan 26, 2012 |
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data |
| Jan 25, 2012 |
Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer |
| Jan 11, 2012 |
Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV |
| Jan 6, 2012 |
Advaxis to Present at 5th Annual OneMedForum San Francisco 2012 |
| Dec 30, 2011 |
Advaxis Receives Additional Financing |
